HIV News and Research

RSS

Peregrine Pharmaceuticals establishes a new Anti-Viral Research Group

Peregrine Pharmaceuticals, Inc. today announced that it has established a new Anti-Viral Research Group in its R&D organization.

7 Oct 2009

Nutra Pharma to launch prescription analgesic for severe chronic pain treatment

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription analgesic, Nyloxin Rx, for the treatment of severe (Stage 3) chronic pain.

7 Oct 2009

HHS and PEPFAR approve the 100th HIV/AIDS antiretroviral drug

The U.S. Department of Health and Human Services (HHS) today marked today marked the recent approval of the 100th antiretroviral drug in association with the President's Emergency Plan for AIDS Relief (PEPFAR), aimed at the prevention, treatment, and care of people infected with and affected by HIV/AIDS worldwide.

7 Oct 2009

Reuters examines health effects of climate change in Africa

Reuters examines how floods, droughts and rising temperatures, thought to be caused by climate change, are compromising African farm lands and leading to health problems for already vulnerable populations - a topic discussed at the "first pan-African climate hearings."

7 Oct 2009

Also in Global Health News: U.S. aid to Somalia; Nigerian health workers strike; male circumcision in Swaziland; PEPFAR in Uganda

The U.S. State and Treasury departments together with USAID have reached an agreement that will allow several aid agencies in Somalia to receive humanitarian grants upon meeting several conditions, "unlock[ing] millions of dollars in relief resources that had been on hold due to US anti-terrorism rules," IRIN reports.

7 Oct 2009

PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies

PDS Biotechnology Corporation today announced that the company has completed GLP toxicology studies of its lead HPV-cancer product. The studies, which included pharmacokinetic (PK) and adsorption, bio-distribution and excretion (ADE) studies in addition to the evaluation of toxicity, all demonstrated a very safe profile of the drug and PDS Biotech's platform Versamune((TM)) technology.

6 Oct 2009

HIV prevalence high among African Americans

HIV prevalence among African Americans is ten times greater than the prevalence among whites. This racial disparity in HIV prevalence has persisted in the face of both governmental and private actions, involving many billions of dollars, to combat HIV.

6 Oct 2009

HIV prevalence among African Americans is ten times greater than the prevalence among whites

6 Oct 2009

CDC study finds fewer secondary schools selling less nutritious foods and beverages

Fewer secondary schools in the United States are selling less nutritious foods and beverages, such as candy and soda, according to a survey from the Centers for Disease Control and Prevention.

6 Oct 2009

BBC examines 'huge imbalance' between funding for HIV/AIDS, other health needs in Uganda

The BBC examines the balance between funding for HIV/AIDS and for the broader health system and other diseases in Uganda.

6 Oct 2009

Antibiotic minocycline may be used for treatment of strokes: Study

The antibiotic minocycline may revolutionize the treatment of strokes. A new study, published in the open access journal BMC Neuroscience, describes the safety and therapeutic efficacy of the drug in animal models.

6 Oct 2009

MSF calls on drug companies to pool HIV patents

Medecins Sans Frontieres (MSF) recently launched an e-mail campaign calling on nine of the world's largest pharmaceutical companies to "release their patents on specific HIV drugs into a collective pool that will increase access and affordability to treatment in developing countries," Inter Press Service reports (Borde, 10/1).

5 Oct 2009

Theraclone and Zenyaku Kogyo sign multi-year research and development agreement

Theraclone Sciences, Inc., a Seattle-based biotechnology company, and Zenyaku Kogyo Co., Ltd., a pharmaceutical company based in Tokyo, today announced that they have entered into a multi-year research and development agreement.

5 Oct 2009

Jon O'Brien's statement on healthcare reform

"This Sunday, the United States Conference of Catholic Bishops holds its annual Respect Life Sunday. On this occasion, we would like to encourage the US bishops to also respect the truth. A recent publication by the USCCB, a brochure entitled Contraception: The Fine Print, and recent polls on healthcare reform prove that the bishops' desire to promote their own views on reproductive health leads them to play fast and loose with the truth.

5 Oct 2009

Phase I clinical trial results to test the safety and immunogenicity of VGX-3100 released

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation.

5 Oct 2009

FHC launches its second-generation female condom in the U.S.

The Female Health Company announced today that its second-generation FC2 Female Condom®, which received regulatory approval from the Food and Drug Administration in March as an HIV prevention method, is now available for purchase in the United States.

3 Oct 2009

Professor's research to transform mobile phones into powerful medical devices

Cell phones have come a long way in the last decade. Today, one can talk, text message, shoot photos and video, send and receive e-mail, and even access the Web. Now imagine a cell phone that can be used to monitor diseases like HIV or malaria and to test water quality after a major disaster like a hurricane or earthquake.

3 Oct 2009

NK cells keep T cells in check: Study

Natural killer, or NK cells, are part of our innate immune system. A healthy body produces them to respond early during infection. They are activated and they kill cells infected with a given virus.

3 Oct 2009

Avexa's ATC Phase III study concludes

Avexa Limited today announced that the apricitabine (ATC) Phase III study will be closed and the data will be subsequently unblinded and analyzed. After extensive interaction with the regulatory authorities and potential partners, the decision was made to evaluate the 24 week data with the results due in the first quarter of 2010.

3 Oct 2009